Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients

AIDS

Volumn 18, Issue 1, 2004, Pages 123-127

  Hasson, Hamid ^a   Gianotti, Nicola ^a   Danise, Anna ^a   Seminari, Elena ^a   Boeri, Enzo ^b   Nozza, Silvia ^a   Castagna, Antonella ^a   Lazzarin, Adriano ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR;

ADULT; ALGORITHM; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CROSS RESISTANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MALE; PHENOTYPE; PRIORITY JOURNAL; VIRUS MUTATION;

ADULT; ANTI-RETROVIRAL AGENTS; CARBAMATES; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; MUTATION; PYRIMIDINONES; RETROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; SULFONAMIDES;

EID: 1642423951     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200401020-00015     Document Type: Article

References (13)

1. Partaledis JA, Yamaguchi K, Tisdale M, Blair EE, Falcione C, Maschera B, et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995, 69:5228-5235.
2. Schmidt B, Korn K, Moschik B, Paatz C, Uberla K, Walter H, et al. Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors. Antimicrob Agents Chemother 2000, 44:3213-3216.
3. Duval X, Lamotte C, Race E, Descamps D, Damond F, Clavel F, et al. Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrob Agents Chemother 2002, 46:570-574.
4. Goujard C, Vincent I, Meynard JL, Choudet N, Bollens D, Rousseau C, et al. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2003, 47:118-123.
5. Randall S, Yeo J, Paterson D, Snowden W, on behalf of the PROB 2004 study team. Amprenavir in PI-naive and PI-experienced pediatric patients: viral genotypic and phenotypic analysis and correlation with treatment outcome. In: 5th International Congress on Drug Therapy in HIV Infection. Glasgow, 2000 [Abstract P226].
6. Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavnavir therapy. Antiviral Ther 2002, 7:165-174.
7. Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2002, 46:2926-2932.
8. Prado JG, Wrin T, Beauchaine J, Ruiz L, Petropoulos CJ, Frost SD, et al. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 2002, 16: 1009-1017.
9. Parkin NT, Chappey C, Petropoulos CJ. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 2003, 17:955-961.
10. Snowden W, Shortino D, Klein A, Harris W, Manohitharajah V, Elston R, et al. Development of amprenavir resistance in NRTI-experienced patients: alternative mechanisms and correlation with baseline resistance to concomitant NRTIs. Antiviral Ther 2000, 5 (Suppl 3):84.
11. Ravela J, Betts BJ., Brun-Vézinet B, Vandamme AM, Descamps D, Van Laethem K, et al. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr 2001, 33:8-14.
12. Gianotti N, Tambussi G, Boeri E, Lazzarin A. Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor. J Biol Regul Homeost Agents 2001, 15:166-169.
13. Parkin N, Chappey C, Maroldo L, Bates M, Hellmann NS, Petropoulos CJ. Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. J Acquir Immune Defic Syndr 2002, 31:128-136.